Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. more
Time Frame | IDYA | Sector | S&P500 |
---|---|---|---|
1-Week Return | -6.06% | -3.72% | -0.05% |
1-Month Return | -0.53% | -1.85% | 2.75% |
3-Month Return | -29.27% | -11.4% | 7.4% |
6-Month Return | -30.64% | -4.41% | 10.47% |
1-Year Return | -25.74% | 4.13% | 27.57% |
3-Year Return | 24.17% | 0.3% | 29.56% |
5-Year Return | 266.9% | 36.62% | 89.3% |
10-Year Return | 132.8% | 106.81% | 206.09% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 19.54M | 27.94M | 50.93M | 23.39M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":38.36,"profit":true},{"date":"2021-12-31","value":54.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.92,"profit":true}] |
Cost of Revenue | 1.25M | 39.70M | 1.73M | 2.10M | 4.01M | [{"date":"2019-12-31","value":3.14,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":4.35,"profit":true},{"date":"2022-12-31","value":5.29,"profit":true},{"date":"2023-12-31","value":10.1,"profit":true}] |
Gross Profit | (1.25M) | 19.54M | 27.94M | 50.93M | 19.38M | [{"date":"2019-12-31","value":-2.44,"profit":false},{"date":"2020-12-31","value":38.36,"profit":true},{"date":"2021-12-31","value":54.86,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":38.05,"profit":true}] |
Gross Margin | (Infinity%) | 100.00% | 100.00% | 100.00% | 82.86% | [{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.86,"profit":true}] |
Operating Expenses | 44.27M | 54.88M | 78.21M | 113.43M | 157.81M | [{"date":"2019-12-31","value":28.05,"profit":true},{"date":"2020-12-31","value":34.78,"profit":true},{"date":"2021-12-31","value":49.56,"profit":true},{"date":"2022-12-31","value":71.88,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (44.27M) | (35.34M) | (50.27M) | (62.50M) | (134.43M) | [{"date":"2019-12-31","value":-4427100000,"profit":false},{"date":"2020-12-31","value":-3534400000,"profit":false},{"date":"2021-12-31","value":-5026800000,"profit":false},{"date":"2022-12-31","value":-6250200000,"profit":false},{"date":"2023-12-31","value":-13442900000,"profit":false}] |
Total Non-Operating Income/Expense | 4.58M | 1.70M | 1.01M | 7.69M | 42.94M | [{"date":"2019-12-31","value":10.68,"profit":true},{"date":"2020-12-31","value":3.95,"profit":true},{"date":"2021-12-31","value":2.36,"profit":true},{"date":"2022-12-31","value":17.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Pre-Tax Income | (41.98M) | (34.49M) | (49.76M) | (58.66M) | (112.96M) | [{"date":"2019-12-31","value":-4197500000,"profit":false},{"date":"2020-12-31","value":-3449500000,"profit":false},{"date":"2021-12-31","value":-4976200000,"profit":false},{"date":"2022-12-31","value":-5865500000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}] |
Income Taxes | (3.53M) | (2.23M) | (2.23M) | (3.85M) | 3.84M | [{"date":"2019-12-31","value":-92,"profit":false},{"date":"2020-12-31","value":-58.07,"profit":false},{"date":"2021-12-31","value":-58.1,"profit":false},{"date":"2022-12-31","value":-100.18,"profit":false},{"date":"2023-12-31","value":100,"profit":true}] |
Income After Taxes | (38.44M) | (32.27M) | (47.53M) | (54.81M) | (116.80M) | [{"date":"2019-12-31","value":-3844200000,"profit":false},{"date":"2020-12-31","value":-3226500000,"profit":false},{"date":"2021-12-31","value":-4753100000,"profit":false},{"date":"2022-12-31","value":-5480800000,"profit":false},{"date":"2023-12-31","value":-11680110500,"profit":false}] |
Income From Continuous Operations | (41.98M) | (34.49M) | (49.76M) | (58.66M) | (112.96M) | [{"date":"2019-12-31","value":-4197500000,"profit":false},{"date":"2020-12-31","value":-3449500000,"profit":false},{"date":"2021-12-31","value":-4976200000,"profit":false},{"date":"2022-12-31","value":-5865500000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (38.44M) | (32.27M) | (47.53M) | (54.81M) | (112.96M) | [{"date":"2019-12-31","value":-3844200000,"profit":false},{"date":"2020-12-31","value":-3226500000,"profit":false},{"date":"2021-12-31","value":-4753100000,"profit":false},{"date":"2022-12-31","value":-5480800000,"profit":false},{"date":"2023-12-31","value":-11296100000,"profit":false}] |
EPS (Diluted) | (4.13) | (1.53) | (1.39) | (1.39) | (1.97) | [{"date":"2019-12-31","value":-413,"profit":false},{"date":"2020-12-31","value":-153,"profit":false},{"date":"2021-12-31","value":-139,"profit":false},{"date":"2022-12-31","value":-139,"profit":false},{"date":"2023-12-31","value":-197,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
IDYA | |
---|---|
Cash Ratio | 22.63 |
Current Ratio | 22.93 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
IDYA | |
---|---|
ROA (LTM) | -15.85% |
ROE (LTM) | -21.10% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
IDYA | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
IDYA | |
---|---|
Trailing PE | NM |
Forward PE | 4.65 |
P/S (TTM) | 555.13 |
P/B | 1.84 |
Price/FCF | NM |
EV/R | 325.34 |
EV/Ebitda | NM |
Ideaya Biosciences Inc (IDYA) share price today is $26.05
Yes, Indians can buy shares of Ideaya Biosciences Inc (IDYA) on Vested. To buy Ideaya Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in IDYA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Ideaya Biosciences Inc (IDYA) via the Vested app. You can start investing in Ideaya Biosciences Inc (IDYA) with a minimum investment of $1.
You can invest in shares of Ideaya Biosciences Inc (IDYA) via Vested in three simple steps:
The 52-week high price of Ideaya Biosciences Inc (IDYA) is $47.73. The 52-week low price of Ideaya Biosciences Inc (IDYA) is $24.71.
The price-to-earnings (P/E) ratio of Ideaya Biosciences Inc (IDYA) is
The price-to-book (P/B) ratio of Ideaya Biosciences Inc (IDYA) is 1.84
The dividend yield of Ideaya Biosciences Inc (IDYA) is 0.00%
The market capitalization of Ideaya Biosciences Inc (IDYA) is $2.18B
The stock symbol (or ticker) of Ideaya Biosciences Inc is IDYA